Key Drivers
- Strong profitability
- Rising leverage
- Weak liquidity
AIAI Summary
AZN is now a higher-beta clinical-execution investment: its durable oncology earnings base supports the downside, but upside—and its premium valuation—depends on tozorakimab and oncology combinations converting into broad approvals and adoption while cash conversion, leverage, and further late-stage setbacks remain key risks.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong profitability
- •Rising leverage
- •Weak liquidity
AZN's strong profitability and R&D-led growth are offset by weakening liquidity, rising debt, softer quarterly cash conversion, and still-demanding valuation.
Price Behavior
Key Price Behavior Insights:
- •Above short-term average
- •Support holding firm
- •Breakout pending
AZN is cautiously bullish over the last month, holding above $163.41 with support at $160–162, but needs a break above $169.66 to confirm further upside.
Sharp pullbacks from the
Sentiment & News
Key News Insights:
- •Regulatory momentum
- •Pipeline resilience
- •Split analyst views
AstraZeneca faces near-term sentiment pressure from trial setbacks and split analyst views, but positive regulatory progress, a strong pipeline outlook and insider buying support a cautiously constructive outlook.
The mixed news flow may sustain volatility, though upcoming pipeline catalysts could improve AZN's valuation outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings